Adrian Gottschalk, Foghorn Therapeutics CEO
Flagship's Foghorn, partnered with Merck and Eli Lilly, gets a partial FDA hold after patient death
The FDA is tapping the brakes on a Flagship-backed biotech’s R&D efforts to develop a new treatment for blood cancers after a patient died in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
